Unum Therapeutics Inc (UMRX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Unum Therapeutics Inc (UMRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8122
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Unum Therapeutics Inc (Unum Therapeutics) is a clinical-stage bio-pharmaceutical company focused on the development and commercialization of novel antibody-coupled cellular immunotherapies to fight cancers. Its pipeline product portfolio include ACTR087 + rituximab, a CD20 targeting chimeric monoclonal antibody to treat non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia; ACTR707 + rituximab as well as ACTR707 + Trastuzumab for the treatment of HER2+ cancers; ACTR087 + SEA-BCMA against multiple myeloma. The company uses its proprietary Antibody-Coupled T-cell Receptor (ACTR) technology in combination of tumor-targeting antibodies which direct individual cytotoxic T-lymphocytes (CTLs) to activate the body’s own immune system to fight hematologic and solid tumor cancers. The company seeks to works in partnership with other biotechnology companies to develop new combinations of ACTR T-cells and tumor targeting antibodies. Unum Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Unum Therapeutics Inc (UMRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Unum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Unum Therapeutics Raises USD65 Million in Series B Financing 11
Unum Therapeutics Raises USD12 Million in Series A Venture Financing 13
Licensing Agreements 14
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 14
Unum Therapeutics Expands Licensing Agreement with National University of Singapore and St. Jude Children’s Research Hospital 15
Equity Offering 17
Unum Therapeutics Raises USD69.2 Million in IPO 17
Unum Therapeutics Raises USD5 Million in Private Placement of Shares 19
Unum Therapeutics Inc – Key Competitors 20
Unum Therapeutics Inc – Key Employees 21
Unum Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 13, 2018: Unum Therapeutics reports second quarter 2018 financial results and provides business update 23
May 14, 2018: Unum Therapeutics Announces First Quarter 2018 Financial Results 25
Research And Development 27
Apr 03, 2017: Unum Therapeutics to present new data on ACTR platform at AACR 2017 27
Corporate Communications 28
Mar 02, 2018: Unum Therapeutics Appoints Karen J. Ferrante And Robert J. Perez As Board Directors 28
Mar 02, 2018: Unum Therapeutics Announces Names Christiana Stamoulis To Additional Role Of President 29
Product News 30
10/27/2017: Unum Therapeutics to Present New Data on its Antibody-Coupled T Cell Receptor Platform at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 30
05/09/2017: Unum Therapeutics to Present Data on its Antibody-Coupled T Cell Receptor Platform at the Upcoming Annual Meeting of the American Society of Gene & Cell Therapy 31
Product Approvals 32
Aug 23, 2017: Unum Therapeutics Announces Active Investigational New Drug Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma 32
Clinical Trials 33
Jul 12, 2018: Unum Therapeutics to Present Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the American Society of Hematology (ASH) Summit on Emerging Immunotherapies for Hematological Diseases 33
Nov 01, 2017: Unum Therapeutics Announces Presentation of Initial Clinical Data from the ATTCK-20-2 Trial and Pre-Clinical Data on its Antibody-Coupled T Cell Receptor Platform at the Upcoming 59th American Society of Hematology (ASH) Annual Meeting 34
Jun 19, 2017: Unum Therapeutics Announces Active Investigational New Drug Application for ACTR707 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Lymphoma 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Unum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Unum Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Unum Therapeutics Raises USD65 Million in Series B Financing 11
Unum Therapeutics Raises USD12 Million in Series A Venture Financing 13
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 14
Unum Therapeutics Expands Licensing Agreement with National University of Singapore and St. Jude Children’s Research Hospital 15
Unum Therapeutics Raises USD69.2 Million in IPO 17
Unum Therapeutics Raises USD5 Million in Private Placement of Shares 19
Unum Therapeutics Inc, Key Competitors 20
Unum Therapeutics Inc, Key Employees 21

List of Figures
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Unum Therapeutics Inc (UMRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Agriterra Ltd (AGTA):企業の財務・戦略的SWOT分析
    Summary Agriterra Ltd (Agriterra) is a provider of agricultural investment and sustainable development solutions. The company provide products such as beef, maize, cocoa and palm oil. It offers business in the fields of beef that conducts cattle ranching, feedlot, abattoir operations and retail unit …
  • Eisai Co Ltd (4523):医療機器:M&Aディール及び事業提携情報
    Summary Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company’s franchise areas in research include neurology and oncology. Eis …
  • Exxon Mobil Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Exxon Mobil Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Exxon Mobil Corp (ExxonMobil) is an integrated oil and gas company that explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petro …
  • Teijin Pharma Ltd-医療機器分野:企業M&A・提携分析
    Summary Teijin Pharma Ltd (Teijin Pharma), a subsidiary of Teijin Ltd develops, manufactures and markets pharmaceutical and home healthcare products. The company offers a range of pharmaceutical products for the treatment of bone and joint diseases, respiratory diseases and cardiovascular and metabo …
  • Hanesbrands Inc (HBI):企業の財務・戦略的SWOT分析
    Hanesbrands Inc (HBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Gilead Sciences Inc (GILD):医療機器:M&Aディール及び事業提携情報
    Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency …
  • Navy Exchange Service Command:企業の戦略・SWOT・財務情報
    Navy Exchange Service Command - Strategy, SWOT and Corporate Finance Report Summary Navy Exchange Service Command - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • BWX Technologies Inc (BWXT):電力:M&Aディール及び事業提携情報
    Summary BWX Technologies Inc (BWXT) is a specialty manufacturer of nuclear components. It designs, engineers, and manufactures precision naval nuclear components, reactors, and nuclear fuel for the US Government. The company also provides special nuclear materials processing and environmental site r …
  • Acushnet Holdings Corp. (GOLF):企業の財務・戦略的SWOT分析
    Acushnet Holdings Corp. (GOLF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Mannatech Inc (MTEX):企業の財務・戦略的SWOT分析
    Mannatech Inc (MTEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Adynxx Inc (ADYX):企業の財務・戦略的SWOT分析
    Summary Adynxx Inc (Adynxx), formerly known as Alliqua BioMedical, Inc, is a clinical stage biopharmaceutical company. It utilizes AYX transcription factor decoys to create therapies with disease changing properties. The company is involved in the development of transcription factor decoy technology …
  • Xerium Technologies Inc:企業の戦略的SWOT分析
    Xerium Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Robert Half International Inc.:企業の戦略・SWOT・財務情報
    Robert Half International Inc. - Strategy, SWOT and Corporate Finance Report Summary Robert Half International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • LG Electronics Inc (066570):電力:M&Aディール及び事業提携情報
    Summary LG Electronics, Inc. (LG Electronics), a subsidiary of LG Corp, manufactures and markets consumer electronics and home appliances. Its product portfolio includes television, monitors, personal computers, audio and video equipment, refrigerators, washing machines, dishwashers, cooking applian …
  • Rafako SA (RFK):電力:M&Aディール及び事業提携情報
    Summary Rafako SA (Rafako), a subsidiary of PBG SA is a power generation equipment manufacturer that designs and distributes boilers and environment protection units. The company provides a range of boilers such as PC boilers, circulating fluidized bed (CFB) boilers, heat recovery steam generator (H …
  • Turkiye Petrol Rafinerileri AS (TUPRS):石油・ガス:M&Aディール及び事業提携情報
    Summary Turkiye Petrol Rafinerileri AS (Tupras), a subsidiary of Enerji Yatirimlari AS, is a downstream energy company. It refines crude oil and marketing of petroleum products. The company operates refineries in Izmit, Izmir, Kirikkale and Batman, and is mainly active in Turkey. Tupras’s refineries …
  • Giner Inc:企業の製品パイプライン分析2018
    Summary Giner Inc (Giner) is a developer of proton exchange membranes and electrochemisty products. The company offers products such as electrolyzer stacks and systems. Its solutions include membrane characterization, dimensionally stable membrane, water quality sensors, trace gas sensors, ozone gen …
  • VeriFone Systems Inc:企業の戦略・SWOT・財務分析
    VeriFone Systems Inc - Strategy, SWOT and Corporate Finance Report Summary VeriFone Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tata Consultancy Services Limited:企業の戦略・SWOT・財務情報
    Tata Consultancy Services Limited - Strategy, SWOT and Corporate Finance Report Summary Tata Consultancy Services Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Diagenode sa-医療機器分野:企業M&A・提携分析
    Summary Diagenode sa (Diagenode) is a provider of biological sample preparation, epigenetics research, and diagnostics assays. The company offers Bioruptor shearing and IP-star automation instruments, reagent kits, and antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. Its produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆